ISSN 1308-8734 | E-ISSN 1308-8742
Original Article
Comparison of the Safety and Efficacy of Loteprednol Etabonate 0.5%/Tobramycin 0.3% with Dexamethasone 0.1%/Tobramycin 0.3% Following Strabismus Surgery
1 Department of Ophthalmology, Atatürk University School of Medicine, Erzurum, Turkey  
Eurasian J Med 2016; 48: 186-188
DOI: 10.5152/eurasianjmed.2016.0264
Key Words: Loteprednol etabonate, dexamethasone, tobramycin, zylet, tobradex, strabismus surgery, corticosteroids, ocular inflammation

Objective: To compare the anti-inflammatory efficacy and safety of 0.5% loteprednol etabonate/0.3% tobramycin (LE/T) and 0.1% dexamethasone/0.3% tobramycin (DM/T) ophthalmic suspensions following strabismus surgery.


Materials and Methods: The records of 40 patients who were treated with either LE/T or DM/T following strabismus surgery were retrospectively reviewed. The recorded signs and symptoms of inflammation and intraocular pressure of the patients at 1 day, 1 week, and 3 weeks after the surgery were evaluated and compared between the groups.


Results: In both groups, reduced inflammation was noted during the follow-up visits. There was no statistically significant difference between the LE/T and DM/T groups with regard to the postoperative scores or measurements, including discomfort, chemosis, secretion, conjunctival hyperemia, and conjunctival gap size (p>0.05), during the follow-up visits. Allergic reactions to the medications were not reported in any patient. Intraocular pressures were within normal limits in both groups.


Conclusion: LE/T was found to be as effective as DM/T in reducing inflammation after strabismus surgery. LE/T, as a new-generation steroid combination product, could be used as a safe and effective anti-inflammatory agent for the treatment of inflammation following strabismus surgery. 

Key Words
Author’s Corner
AVES | Copyright © 2018 Atatürk University Faculty of Medicine | Latest Update: 20.07.2018